ROCKVILLE, Md., May 12, 2021 /PRNewswire/ — Emmes (the “Company”), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation and a portfolio company of Behrman Capital, today announced that it has acquired Orphan Reach, a CRO specialized in clinical research related to rare diseases. Financial terms of the transaction were not disclosed.
Whether it’s “Mom and Pop” retail storefronts, family-run home services companies or life science companies developing innovative, life saving products, family owned-and-operated businesses are the lifeblood of the global economy.
Emmes President and CEO, Dr. Christine Dingivan
The combination of a booming biotech market with an additional surge of hiring by vaccine and diagnostic companies in Maryland has resulted in record-low unemployment and competition for talent at an all-time high.
Emmes Corp. Appoints Dr. Nilay Shay as VP of Strategic Partnerships and Medical Officer Dr. Nilay Shah is vice president of strategic partnerships and medical officer. He started his career practicing [….]
These Philosophies Have Propelled The Emmes Corporation to Become a Leading International Clinical Research Organization
These Philosophies Have Propelled The Emmes Corporation to Become a Leading International Clinical Research Organization Emmes Shows That Doing Good is Good for Science, Medicine and Business The [….]